When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MBIO - Mustang Bio down 18% on less effect of gene therapy on older XSCID patients
Mustang Bio Inc.
Thinly traded Mustang Bio (MBIO-17.7%) is down on almost 4x higher volume, albeit on turnover of less than 1M shares, in apparent reaction to updated data from ongoing Phase 1/2 clinical trials evaluating lentiviral gene therapy MB-107 in patients with X-linked severe combined immunodeficiency (XSCID), an inherited disorder also known as "Bubble Boy Disease" since it occurs almost exclusively in males who lack the necessary immune cells to fight infections. The results were presented as ASH in Orlando.
More news on: Mustang Bio, Inc., Healthcare stocks news, Stocks on the move,